Consensus target rises to USD 4.64 for Lexicon Pharmaceuticals stock

Published on 10/16/2026 at 04:55 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor set an Overweight rating and USD 8.00 target on September 28, 2026. SONATA-HCM data are due in Q1 2027 for Lexicon Pharmaceuticals stock.

Pipeline timing and financial pressure

The average one-year target reached USD 4.64 on October 2, 2026.
Second-quarter revenue was USD 0.7 million and net loss was USD 31.8 million.
SONATA-HCM top-line data are expected in the first quarter of 2027.

LXRX, US5288723027, Illustration mit AI erstellt.

Lexicon Pharmaceuticals stock received a higher average one-year target of USD 4.64 on October 2, 2026, up from USD 3.93, according to Nasdaq. The revision puts clinical execution at the center of the valuation case, with the next major readout expected in the first quarter of 2027.

Three milestones since August

On August 6, 2026, Lexicon reported second-quarter revenue of USD 0.7 million, compared with USD 28.9 million in the second quarter of 2025, while its net loss reached USD 31.8 million versus net income of USD 3.3 million a year earlier, Benzinga reported. On September 28, 2026, Cantor Fitzgerald began coverage with an Overweight rating and a USD 8.00 price target, according to MarketBeat. On October 2, 2026, the average target reached USD 4.64 from USD 3.93.

What does USD 4.64 mean?

The Nasdaq report puts the USD 4.64 average target 154.81 percent above the USD 1.82 closing price cited for October 1, 2026. That gap is a valuation comparison, not a forecast of the eventual trading price. The latest quarterly figures explain the sensitivity: revenue declined by USD 28.2 million year over year, while research and development expenses rose to USD 17.4 million from USD 15.7 million.

Clinical dates set the next test

Lexicon expects to complete its ZYNQUISTA new drug application resubmission during the fourth quarter of 2026, according to Benzinga. The same transcript says top-line results from the over-enrolled SONATA-HCM Phase 3 study are expected in the first quarter of 2027, giving the pipeline a defined clinical milestone.

Market value and balance sheet

Lexicon had a market capitalization of USD 734.2 million as of October 15, 2026. Cash, cash equivalents, and short-term investments totaled USD 190.6 million on June 30, 2026, compared with USD 125.2 million at December 31, 2025. The company also announced a USD 100.0 million Hercules Capital debt facility in May 2026.